miRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
MRG-106 granted orphan-drug status for the treatment of mycosis fungoides by U.S. Food and Drug Administration (FDA) miRagen’s collaboration with Servier extended with the objective to start testing MRG-110 in humans within a year MRG-106 clinical data to …